ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
01 Août 2023 - 1:00PM
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host
a conference call and live webcast on Tuesday, August 8, 2023 at
8:30 a.m. EDT to report financial results for the second quarter
2023 and provide business updates.
To access the conference call, please register
here. Registrants will receive the dial-in number and unique PIN.
It is recommended that you join 10 minutes before the event, though
you may pre-register at any time. A live webcast of the call will
be available under the “Events and Presentations” tab in the
Investors section of the ADC Therapeutics website at
ir.adctherapeutics.com. The archived webcast will be available for
30 days following the call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a
commercial-stage global leader and pioneer in the field of antibody
drug conjugates (ADCs). The Company is advancing its proprietary
ADC technology to transform the treatment paradigm for patients
with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA
(loncastuximab tesirine-lpyl) received accelerated approval by the
FDA and conditional approval from the European Commission for the
treatment of relapsed or refractory diffuse large B-cell lymphoma
after two or more lines of systemic therapy. ZYNLONTA is also in
development in combination with other agents and in earlier lines
of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple
ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle),
Switzerland and has operations in London, the San Francisco Bay
Area and New Jersey. For more information, please visit
https://www.adctherapeutics.com/ and follow the Company on Twitter
and LinkedIn.
ZYNLONTA® is a registered trademark of ADC
Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. In some cases you
can identify forward-looking statements by terminology such as
“may”, “will”, “should”, “would”, “expect”, “intend”, “plan”,
“anticipate”, “believe”, “estimate”, “predict”, “potential”,
“seem”, “seek”, “future”, “continue”, or “appear” or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: the success of the Company’s
updated corporate strategy including operating efficiencies,
capital deployment and portfolio prioritization; the Company’s
ability to achieve the 2023 net product sales guidance for
ZYNLONTA® and the decrease in total operating expenses for 2023 and
2024, the expected cash runway into the middle of 2025, the
effectiveness of the new commercial go-to-market strategy and the
Company’s ability to continue to commercialize ZYNLONTA® in the
United States and future revenue from the same; Swedish Orphan
Biovitrum AB (Sobi®) ability to successfully commercialize
ZYNLONTA® in the European Economic Area and market acceptance,
adequate reimbursement coverage, and future revenue from the same;
our strategic partners’, including Mitsubishi Tanabe Pharma
Corporation and Overland Pharmaceuticals, ability to obtain
regulatory approval for ZYNLONTA® in foreign jurisdictions, and the
timing and amount of future revenue and payments to us from such
partnerships; the Company’s ability to market its products in
compliance with applicable laws and regulations; the Company’s
expectations regarding the impact of the Infrastructure Investment
and Jobs Act; the timing and results of the Company’s or its
partners’ research projects or clinical trials including LOTIS 5, 7
and 9, ADCT 901, 601 and 602, the timing and outcome of regulatory
submissions and actions by the FDA or other regulatory agencies
with respect to the Company’s products or product candidates; the
nature, frequency and severity of adverse events; the ability to
complete clinical trials on expected timelines, if at all;
projected revenue and expenses; the Company’s indebtedness,
including Healthcare Royalty Management and Blue Owl and Oaktree
facilities, and the restrictions imposed on the Company’s
activities by such indebtedness, the ability to repay such
indebtedness and the significant cash required to service such
indebtedness; and the Company’s ability to obtain financial and
other resources for its research, development, clinical, and
commercial activities. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the “Risk Factors” section of the Company's Annual
Report on Form 20-F and in the Company's other periodic reports and
filings with the Securities and Exchange Commission. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance, achievements or
prospects to be materially different from any future results,
performance, achievements or prospects expressed in or implied by
such forward-looking statements. The Company cautions investors not
to place undue reliance on the forward-looking statements contained
in this document. The Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by law.
CONTACTS:
InvestorsEugenia LitzADC
TherapeuticsEugenia.Litz@adctherapeutics.com+44 7879 627205+1
908-723-2350
MediaNicole RileyADC
TherapeuticsNicole.Riley@adctherapeutics.com+1 862-926-9040
ADC Therapeutics (NYSE:ADCT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
ADC Therapeutics (NYSE:ADCT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024